Company intelligence / Profile preview

NanoCarrier Co., Ltd.

Kashiwa City, Chiba, Japannanocarrier.co.jp ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

NanoCarrier has developed a proprietary micellar nanoparticle DDS platform for targeted drug delivery with reduced side effects and improved efficacy. The company’s pipeline includes late-stage clinical candidates for various cancers and nucleic acid drugs enabled by its merger with AccuRna Inc. Clinical results have demonstrated safety and effectiveness for their delivery systems in oncology settings; several programs are partnered or licensed-in from global biotech firms

Therapeutic areas: OncologyInfectious DiseasesRheumatology
Modalities: Small moleculessiRNAmRNAantisense oligonucleotides (ASO)protein therapeutics
Industry: Biotech

Partnerships

VBL Therapeutics – exclusive Japanese rights to develop/commercialize VB‑111 for glioblastoma & ovarian cancers etc.

Beyond the preview

Go deeper on NanoCarrier Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoCarrier Co., Ltd..